Q: Atara Biotherapeutics (NASDAQ:ATRA) has announced presentation of preclinical data of ATA3219 at American Society of Hematology.
Their allogeneic CAR T-cell therapy targeting CD19, Bayer has also just entered into an exclusive worldwide license agreement, for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors with Atara.
What is your opinion on this company and it's medium and long term investment potential.
Their allogeneic CAR T-cell therapy targeting CD19, Bayer has also just entered into an exclusive worldwide license agreement, for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors with Atara.
What is your opinion on this company and it's medium and long term investment potential.